<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655690</url>
  </required_header>
  <id_info>
    <org_study_id>NN1471-4612</org_study_id>
    <secondary_id>U1111-1247-7440</secondary_id>
    <secondary_id>2020-000665-16</secondary_id>
    <nct_id>NCT04655690</nct_id>
  </id_info>
  <brief_title>A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Trial Investigation the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0471-0119 in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at the safety of the new medicine, insulin NNC0471-0119, its&#xD;
      concentrations in the blood and effect on blood sugar for the treatment of type 1 diabetes.&#xD;
      Insulin NNC0471-0119 will be compared to faster aspart. The purpose of this study is to test&#xD;
      how insulin NNC0471-0119 is tolerated by participants body, how it is transported in&#xD;
      participants bloodstream, how long it stays there and how the blood sugar is lowered compared&#xD;
      to faster aspart. Participants will get either the new insulin NNC0471-0119 or faster&#xD;
      aspart-which treatment participants get is decided by chance. It is the first time insulin&#xD;
      NNC0471-0119 is tested in people. Faster aspart is a globally used medication for treatment&#xD;
      of diabetes mellitus. Participants will get one single injection in a fasting state which&#xD;
      will take place at the study site. The medicine will be injected under the skin in the&#xD;
      stomach. The study will last for about 13-53 days, depending on individual visit schedule.&#xD;
      Participants will have four clinic visits with the study doctor, one of which will require an&#xD;
      in-house visit period of 3 days. During the in-house visit, two intravenous cannulas will be&#xD;
      inserted for sampling of blood and infusion of insulin. Participants cannot be in the study&#xD;
      if the study doctor thinks that there are risks to their health. Women: Women cannot take&#xD;
      part if they are of childbearing potential.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">November 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>From investigational medicinal product (IMP) administration at day 1 (Visit 2) and up to 22 days post IMP administration (Visit 3)</time_frame>
    <description>Number of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>0 to 24 hours after IMP administration</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCNNC0471-0119,0-30 min/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 0-30 min and 0-t, where t is the last observed time point with insulin concentration above lower limit of quantification (LLOQ).</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
    <description>% (Percent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCNNC0471-0119,2h-t/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 2 hours to t and 0 to t, where t is the last observed time point with insulin concentration above LLOQ.</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCNNC0471-0119, 0-t: Area under the serum NNC0471-0119 concentration-time curve from 0 to t, where t is the last observed time point with insulin concentration above LLOQ.</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
    <description>h*pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,NNC0471-0119: Maximum observed serum NNC0471- 0119 concentration</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,NNC0471-0119: Time to maximum observed serum NNC0471-0119 concentration</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, NNC0471-0119: Terminal half-life for NNC0471-0119</measure>
    <time_frame>0 to 12 hours after IMP administration</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>NNC0471-0119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomised to NNC0471-0119</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faster aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomised to faster aspart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0471-0119</intervention_name>
    <description>Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.</description>
    <arm_group_label>NNC0471-0119</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fast-acting insulin aspart</intervention_name>
    <description>Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.</description>
    <arm_group_label>Faster aspart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subject or female subject of non-childbearing potential. Non-childbearing&#xD;
             potential being defined as surgically sterilised (i.e. documented hysterectomy,&#xD;
             bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as&#xD;
             no menses for 12 months without an alternative medical cause) prior to the day of&#xD;
             screening.&#xD;
&#xD;
          -  Aged 18-55 years (both inclusive) at the time of signing informed consent.&#xD;
&#xD;
          -  Diagnosed with Type 1 Diabetes Mellitus (T1DM) greater than or equal to 1 year prior&#xD;
             to the day of screening.&#xD;
&#xD;
          -  Current total daily bolus insulin treatment less than 0.7(I)U/kg/day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to investigational medicinal products (IMPs) or&#xD;
             related products.&#xD;
&#xD;
          -  Participation in any clinical trial of an approved or non-approved IMP within 90 days&#xD;
             before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

